Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant718 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04286711 | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 52 | China Medical University, ChinaOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT04263870 | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(CTSCAPOXSEA) | unknown | Phase 2 | 36 | Sichuan UniversityOTHER | 1 |
| Feb 11, 2020 |
| clinicaltrials |
| NCT04065282 | The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma. | unknown | Phase 2 | 36 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04258644 | Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer | unknown | Phase 2 | 30 | Beijing Friendship HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT04258657 | Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer | unknown | Phase 2 | 20 | Beijing Friendship HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT02845986 | Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer(CLASS-04) | unknown | Phase 2 | 251 | Fujian Medical UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03192735 | Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer | unknown | Phase 2 | 50 | Chang-Ming Huang, Prof.OTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03290209 | Clinical Outcomes of Laparoscopic D1 Versus D2 Lymphadenectomy for Elderly Patients With Advanced Gastric Cancer(D1D2) | unknown | Phase 2 | 160 | Fujian Medical UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03957564 | Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer | unknown | Phase 2 | 40 | Affiliated Hospital of Qinghai UniversityOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04202484 | Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | unknown | Phase 2 | 116 | Zhejiang Cancer HospitalOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04182724 | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 57 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04005365 | Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer | unknown | Phase 2 | 78 | Yijing HeOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02585908 | Safety and Efficacy of γδ T Cell Against Gastric Cancer | unknown | Phase 1 / Phase 2 | 120 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT04155671 | POF Versus FOLFOX Plus IP Paclitaxel in AGC | unknown | Phase 2 | 260 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 7, 2019 | clinicaltrials |
| NCT04149015 | Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 4, 2019 | clinicaltrials |
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | unknown | Phase 2 | 116 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 9, 2019 | clinicaltrials |
| NCT04089657 | Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens(ASGARD) | unknown | Phase 2 | 40 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 13, 2019 | clinicaltrials |
| NCT03263741 | Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer | unknown | Phase 2 | 20 | Affiliated Hospital of Qinghai UniversityOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03829345 | A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer(SOLAR) | unknown | Phase 2 | 54 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03229096 | Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer | unknown | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT04001569 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 49 | Seoul National University Bundang HospitalOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT03990103 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | unknown | Phase 2 | 66 | China Medical University, ChinaOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT03966118 | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma(AIO-STO-0218) | unknown | Phase 2 | 59 | P. C. Thuss-PatienceOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03954756 | Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer | unknown | Phase 2 | 35 | Henan Cancer HospitalOTHER_GOV | 0 | May 17, 2019 | clinicaltrials |
| NCT03817411 | Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer | unknown | Phase 2 | 90 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03694977 | Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer | unknown | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer(MICADO) | unknown | Phase 2 | 51 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02486601 | NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma(FOXAGAST) | unknown | Phase 2 | 55 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02177552 | Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma(SEED) | unknown | Phase 2 | 98 | Rigshospitalet, DenmarkOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03837301 | Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) | unknown | Phase 2 | 88 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02697838 | Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03701373 | Maintenance Treatment With S-1 in Gastric Cancer Patients | unknown | Phase 2 | 200 | Sun Yat-sen UniversityOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT02404753 | A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy(REALIZATION) | unknown | Phase 2 | 102 | Peking UniversityOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT03564834 | Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients | unknown | Phase 2 | 180 | Peking UniversityOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT03599778 | XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma | unknown | Phase 1 / Phase 2 | 52 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03575637 | Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer | unknown | Phase 2 | 180 | Peking UniversityOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02596256 | Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301) | unknown | Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT02942329 | Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT03427684 | Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 18 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 9, 2018 | clinicaltrials |
| NCT03428425 | A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | unknown | Phase 2 | 38 | Hebei Medical UniversityOTHER | 0 | Feb 9, 2018 | clinicaltrials |
| NCT03410732 | Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer | unknown | Phase 2 | 120 | LanZhou UniversityOTHER | 1 | Jan 25, 2018 | clinicaltrials |
| NCT03400592 | Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma(NIEGA) | unknown | Phase 2 | 55 | Peking UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT03399253 | Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor | unknown | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT03392103 | Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection | unknown | Phase 2 | 48 | Zhongnan HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02461407 | Study of Anlotinib in Patients With Gastric Cancer(ALTER0503) | unknown | Phase 2 / Phase 3 | 378 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02777801 | Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Oct 13, 2017 | clinicaltrials |
| NCT02509806 | Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer | unknown | Phase 2 / Phase 3 | 48 | Hebei Medical UniversityOTHER | 1 | Oct 9, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2020source: clinicaltrials